Welcome to our dedicated page for Relmada Therapeutics news (Ticker: RLMD), a resource for investors and traders seeking the latest updates and insights on Relmada Therapeutics stock.
Relmada Therapeutics, Inc. (Nasdaq: RLMD) is a clinical-stage biotechnology company focusing on the development of treatments for central nervous system (CNS) disorders, particularly major depressive disorder (MDD). The company's lead product candidate, REL-1017, is a new chemical entity (NCE) and NMDA receptor channel blocker. It is currently being evaluated in late-stage clinical trials as an adjunctive treatment for MDD in adults.
REL-1017 has shown promise in clinical studies, demonstrating rapid and sustained improvements in depressive symptoms with a favorable safety profile. The ongoing clinical development program includes two Phase 3 trials: Reliance II (Study 302) and Relight (Study 304), which are designed to assess the efficacy and safety of REL-1017 in patients with MDD who have an inadequate response to their current antidepressant therapies.
Relmada Therapeutics is also advancing a novel non-psychedelic/low dose psilocybin program (REL-P11) for the treatment of metabolic conditions. Initial preclinical studies have shown significant therapeutic potential in improving metabolic parameters, and the company plans to initiate Phase 1 and Phase 2a trials in obese patients with steatotic liver disease.
In recent corporate updates, Relmada has reported significant progress in its clinical development plans, with study enrollments proceeding as expected and additional preclinical and Phase 1 studies supporting future regulatory submissions. The company is well-funded to continue its research and development activities, aiming for multiple clinical milestones and potential regulatory filings in the near future.
Relmada Therapeutics (Nasdaq: RLMD) announced the results of the RELIANCE I study, evaluating REL-1017 for Major Depressive Disorder. The study did not achieve its primary endpoint of significant improvement in depression symptoms compared to placebo. Despite this, the REL-1017 treatment arm showed a MADRS reduction of 15.1 points versus 12.9 points for placebo. A post-hoc analysis excluding two high enrolling centers revealed a 4.1 point difference. Relmada is implementing protocol changes for its ongoing RELIANCE II trial based on findings from RELIANCE I and III.
Relmada Therapeutics (Nasdaq: RLMD) provided an update on its financial results for Q3 and the first nine months of 2022. The company reported a net loss of $39.4 million, or $1.31 per diluted share, for Q3, improving from a net loss of $42.6 million in the same period last year. For the nine months, the net loss rose to $119.1 million, compared to $91.4 million in 2021. Relmada is evaluating data from its Phase 3 RELIANCE III trial for REL-1017 for major depressive disorder (MDD) while expecting results from ongoing studies in 2022 and 2023. The company maintains a strong balance sheet with $184.2 million in cash.
Relmada Therapeutics (Nasdaq: RLMD) announced it will release its financial results for Q3 and nine months ended September 30, 2022, after market close on November 10, 2022. A conference call and webcast will follow at 4:30 PM Eastern Time.
The company continues to advance REL-1017, a novel NMDA receptor channel blocker, in late-stage development for major depressive disorder, reporting positive results from its Phase 2 trial.
Relmada Therapeutics, Inc. (Nasdaq: RLMD) announced that its RELIANCE III study of REL-1017, aimed at treating Major Depressive Disorder (MDD), did not meet its primary endpoint of statistically significant symptom improvement compared to placebo. The treatment group showed a MADRS reduction of 14.8 points, marginally higher than the placebo's 13.9 points. Despite these disappointing results, the safety profile of REL-1017 remained favorable. Relmada continues enrollment in two ongoing Phase 3 trials (RELIANCE I and II) for REL-1017 as an adjunctive treatment for MDD.
Relmada Therapeutics (Nasdaq: RLMD) has completed patient treatment in the Phase 3 RELIANCE III trial for its NMDA receptor channel blocker, REL-1017, aimed at treating major depressive disorder (MDD). Top-line data is expected early next quarter, following the FDA's Fast Track Designation for REL-1017. This trial is part of a broader clinical program including two other Phase 3 studies and an open-label safety study. Previous trials have shown promising antidepressant effects and a favorable safety profile for REL-1017.
Relmada Therapeutics (Nasdaq: RLMD) announced its corporate update and preliminary financial results for the second quarter of 2022. The FDA granted Fast Track designation for REL-1017 to treat major depressive disorder (MDD). The company appointed John Hixon as Head of Commercial to prepare for market entry. Financials revealed a net loss of $39.9 million, increasing from $26.6 million year-over-year, while R&D expenses rose to $24.6 million. As of June 30, 2022, cash and equivalents stood at approximately $212 million. Key trial results for REL-1017 are anticipated in the latter half of 2022.
Relmada Therapeutics (Nasdaq: RLMD) announced that the FDA has granted Fast Track designation to its novel NMDA receptor blocker, REL-1017, for treating major depressive disorder (MDD). This designation accelerates the development and review process for drugs addressing serious conditions. REL-1017 is currently involved in a Phase 3 trial as a monotherapy and supporting adjunctive treatment studies. The drug showed promising results in Phase 2 trials, demonstrating rapid and sustained antidepressant effects with a favorable safety profile.
Relmada Therapeutics (Nasdaq: RLMD) announced it will report Q2 2022 financial results on August 11, 2022, after market close. A conference call and live audio webcast are scheduled for the same day at 4:30 PM ET. The company’s lead product, REL-1017, is in late-stage development for major depressive disorder (MDD) and has shown promising results in a Phase 2 trial, demonstrating rapid and sustained antidepressant effects compared to placebo. The trial also confirmed a favorable safety profile, as previously noted in Phase 1 studies.
Relmada Therapeutics (Nasdaq: RLMD) announced the appointment of John Hixon as the new Head of Commercial, bringing over 36 years of experience in biopharmaceutical marketing. This strategic addition aims to enhance commercial efforts for REL-1017, a promising treatment for major depressive disorder (MDD), which is nearing Phase III clinical trial readouts. Hixon emphasized REL-1017's potential to transform treatment for patients with MDD, supported by positive Phase 2 trial results showing significant antidepressant effects and favorable safety profiles.
Relmada Therapeutics (NASDAQ: RLMD), a late-stage biotechnology firm focused on central nervous system diseases, announced that CEO Sergio Traversa will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 10:40am PT / 1:40pm ET. The event will discuss the company's lead program, REL-1017, a new chemical entity in late-stage development for major depressive disorder (MDD). A webcast of the presentation will be available, with an archived replay accessible for 90 days.
FAQ
What is the current stock price of Relmada Therapeutics (RLMD)?
What is the market cap of Relmada Therapeutics (RLMD)?
What is Relmada Therapeutics' primary focus?
What is REL-1017?
What are Reliance II and Relight?
What recent progress has Relmada reported?
What is the REL-P11 program?
How has REL-1017 performed in clinical studies?
What are the anticipated milestones for Relmada in 2024?
Is Relmada financially stable to continue its research?
What is the significance of REL-1017's mechanism of action?
How can I learn more about Relmada Therapeutics?
